Breadcrumb
Dokumente & Medien
Answering Complex Hierarchy Questions in Network Meta-analysis
Answering Complex Hierarchy Questions in Network Meta-analysis
Version 1.0 Genehmigt- Dokumententyp
- EXTERNAL_DOCUMENT
- Erweiterung
- png
- Größe
- 77 KB
- Geändert
- 21.10.22 13:31 von mir mir
- Erstellt
- 21.10.22 13:31 von mir mir
- Ort
- PUBLIC
- Bewertungen
-
-
Version 1.0Von mir mir, am 21.10.22 13:31Kein Änderungsprotokoll
Kurzfassung
Background: Network meta-analysis estimates all relative effects between competing treatments and can produce a treatment hierarchy from the most to the least desirable option according to a health outcome. While about half of the published network meta-analyses present such a hierarchy, it is rarely the case that it is related to a clinically relevant decision question.
Methods: We first define treatment hierarchy and treatment ranking in a network meta-analysis and suggest a simulation method to estimate the probability of each possible hierarchy to occur. We then propose a stepwise approach to express clinically relevant decision questions as hierarchy questions and quantify the uncertainty of the criteria that constitute them. The steps of the approach are summarized as follows: a) a question of clinical relevance is defined, b) the hierarchies that satisfy the defined question are collected and c) the frequencies of the respective hierarchies are added; the resulted sum expresses the certainty of the defined set of criteria to hold. We then show how the frequencies of all possible hierarchies relate to common ranking metrics.
Results: We exemplify the method and its implementation using two networks. The first is a network of four treatments for chronic obstructive pulmonary disease where the most probable hierarchy has a frequency of 28%. The second is a network of 18 antidepressants, among which Vortioxetine, Bupropion and Escitalopram occupy the first three ranks with frequency 19%.
Conclusions: The developed method offers a generalised approach of producing treatment hierarchies in NMA, which moves towards attaching treatment ranking to a clear decision question, relevant to all or a subset of competing treatments.
Das COMPAR-EU-Projekt wurde durch das Forschungs- und Innovationsprogramm Horizont 2020 der Europäischen Union unter der Fördervereinbarung Nr. 754936 gefördert.
Sie enthält jetzt die vollständigen Ergebnisse für Diabetes, und im Laufe des Sommers 2022 werden die Ergebnisse für Adipositas, COPD und Herzinsuffizienz vervollständigt. Die Plattform wird auch in den nächsten Monaten erweitert und verbessert.